Get started
Author

Fangmin Li

Observed name: Li, Fangmin
ORCID: 0009-0003-6949-204X
Observed ORCID: 0009-0003-6949-204X
OpenAlex ID: A5101955344
Effects and Molecular Mechanism of GST-Irisin on Lipolysis and Autocrine Function in 3T3-L1 Adipocytes
2016 · Shanshan Gao, Fangmin Li, et al. · PLoS ONE · 63
PDF
Hesperetin ameliorates lipopolysaccharide-induced acute lung injury in mice through regulating the TLR4–MyD88–NF-κB signaling pathway
2019 · Naigang Wang, Cuiping Geng, et al. · Archives of Pharmacal Research · 46
LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway
2024 · Hongying Wang, Lei Wang, et al. · Journal of Experimental & Clinical Cancer Research · 22
PDF
Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · Cancer Research · 18
Protozoan‐Derived Cytokine‐Transgenic Macrophages Reverse Hepatic Fibrosis
2024 · Ying Chen, Jie Wang, et al. · Advanced Science · 13
PDF
Human milk-derived MANF, as an immuno‐nutritional factor, maintains the intestinal epithelial barrier and protects against necrotizing enterocolitis
2023 · Jie Wang, Nan Zhou, et al. · The Journal of Nutritional Biochemistry · 7
IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia
2025 · Lijun Hui, Jing Xiao, et al. · Blood Advances · 5
PDF
Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape
2026 · Jiasheng Zhang, Xianhui Meng, et al. · Journal for ImmunoTherapy of Cancer · 3
Toxoplasma calcium-dependent protein kinases 3 mediates M1 macrophage polarization by targeting host Arginase-1
2025 · Ran An, Fang Liu, et al. · Parasites & Vectors · 2
PDF
Toxoplasma gondii effector GRA35 mediates neuronal damage via ER stress and mitochondria-associated apoptosis
2026 · Jie Wang, Ying Chen, et al. · Virulence · 1
PDF
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2023 · Yifan Liu, Hongying Wang, et al. · 1
Figure S2 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S1 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S4 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S7 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S5 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
Figure S8 from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Supplementary Data from Targeting the Immunoglobulin IGSF9 Enhances Antitumor T-cell Activity and Sensitivity to Anti–PD-1 Immunotherapy
2025 · Yifan Liu, Hongying Wang, et al.
PDF
Figure S8 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Supplementary Data from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S6 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S7 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Figure S3 from Targeting the immunoglobulin IGSF9 enhances anti-tumor T cell activity and sensitivity to anti-PD-1 immunotherapy
2024 · Yifan Liu, Hongying Wang, et al.
Works count: 57
Citation count: 181
H-index: 6
I10-index: 5
Year
Topic
Type